SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
153.02
+6.84 (+4.68%)
As of 1:24PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close146.18
Open147.58
Bid152.170 x 900
Ask152.350 x 1000
Day's Range145.50 - 153.02
52 Week Range79.88 - 188.82
Volume185,916
Avg. Volume596,547
Market Cap7.206B
Beta (3Y Monthly)3.10
PE Ratio (TTM)N/A
EPS (TTM)-6.389
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est200.13
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents2 days ago

    Edited Transcript of SAGE earnings conference call or presentation 19-Feb-19 1:00pm GMT

    Q4 2018 SAGE Therapeutics Inc Earnings Call

  • Sage Therapeutics Inc (SAGE) Q4 2018 Earnings Conference Call Transcript
    Motley Fool3 days ago

    Sage Therapeutics Inc (SAGE) Q4 2018 Earnings Conference Call Transcript

    SAGE earnings call for the period ending December 31, 2018.

  • Business Wire3 days ago

    Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

    Planned U.S. commercial launch of ZULRESSO™ injection, if approved, on track for June 2019, based on PDUFA target date of March 19, 2019 and anticipated DEA schedulin

  • ACCESSWIRE3 days ago

    SAGE Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / February 19, 2019 / SAGE Therapeutics, Inc. (NASDAQ: SAGE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 19, 2019 at ...

  • FOMC minutes, Walmart earnings – What to know in the week ahead
    Yahoo Finance5 days ago

    FOMC minutes, Walmart earnings – What to know in the week ahead

    The release of the Federal Reserve's meeting minutes Wednesday will be a focal point this week.

  • Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
    Investor's Business Daily8 days ago

    Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst

    An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.

  • Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored
    Bloomberg8 days ago

    Biotech Hedge Fund Bailed on Drugmaker Before Its Depression Treatment Scored

    Baker Bros., which was among the top 20 holders of the biotech stock at the end of September, sold its final 567,497 shares by the end of 2018, according to a regulatory filing this week. Baker Bros. didn’t immediately respond to a request for comment. To be sure, the New York-based hedge fund held just under half a million shares back in 2017 when Sage approached $100 per share after its lead asset saw success in another clinical trial.

  • Here's Why Sage Therapeutics Gained 48.9% in January
    Motley Fool12 days ago

    Here's Why Sage Therapeutics Gained 48.9% in January

    The pharma company reported positive results from an important phase 3 trial.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.

    SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 15. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding SAGE totaled $4.45 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GlobeNewswire14 days ago

    Factors of Influence in 2019, Key Indicators and Opportunity within New Relic, Clean Harbors, Sage Therapeutics, Accelerate Diagnostics, Fortinet, and Colfax — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire15 days ago

    Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that, on February 1, 2019, the Compensation Committee of Sage’s Board of Directors granted non-qualified stock options to purchase an aggregate of 8,500 shares of its common stock, and 750 performance restricted stock units (PSUs) to two new employees under Sage’s 2016 Inducement Equity Plan. The 2016 Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Sage (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Sage, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.

  • Business Wire17 days ago

    Sage Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 19, 2019

    Sage Therapeutics , a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, February 19, 2019 at 8:00 a.m.

  • Here are Boston-area biotechs pursuing Parkinson's treatments
    American City Business Journals22 days ago

    Here are Boston-area biotechs pursuing Parkinson's treatments

    The continued need for new Parkinson's disease treatments drew attention this week, with one local gene therapy biotech striking a $165 million collaboration deal, while another companies' drug was rejected by the FDA.

  • ACCESSWIRE29 days ago

    Three Companies Using AI and Innovation to Lead Healthcare Sector

    HOUSTON, TX / ACCESSWIRE / January 24, 2019 / Healthcare is quickly being disrupted by artificial intelligence. In fact, AI is quickly proving it can spot warning signs of disease before we're even aware of it ourselves. "Artificial intelligence could also use the way we look to help us predict future disease.

  • Business Wirelast month

    Sage Therapeutics Appoints Elizabeth Barrett and George Golumbeski to Board of Directors

    Sage Therapeutics (SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the addition of Elizabeth (Liz) Barrett and George Golumbeski, Ph.D., to the company’s board of directors. As Sage continues to advance its programs in development, adding an executive with Liz’s expertise in scaling businesses and launching products globally will be invaluable,” said Jeff Jonas, M.D., chief executive officer of Sage. “We are just as excited to announce that George Golumbeski will be joining our board.

  • Ligand (LGND) Takes a Hit on Citron's Negative Research Report
    Zackslast month

    Ligand (LGND) Takes a Hit on Citron's Negative Research Report

    Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.

  • Citron Says Ligand Has 80% Downside in Explosive Note
    Investopedialast month

    Citron Says Ligand Has 80% Downside in Explosive Note

    Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Amicus Therapeutics and Sage Therapeutics

    NEW YORK, NY / ACCESSWIRE / January 16, 2019 /U.S. markets rose on Tuesday as Netflix helped push the tech sector higher after announcing it would raise the price of its monthly membership. Tech giants ...

  • 3 Small-Cap Stocks With Big-Cap Potential
    Motley Foollast month

    3 Small-Cap Stocks With Big-Cap Potential

    Sierra Wireless, Innovative Industrial Properties, and Axsome Therapeutics could generate multibagger returns over the long term.

  • Here's How The Government Shutdown Will Affect These Medical Stocks
    Investor's Business Dailylast month

    Here's How The Government Shutdown Will Affect These Medical Stocks

    The longest government shutdown in U.S. history could logjam drug approvals and clinical tests at the Food and Drug Administration, analysts said Tuesday. Several biotech stocks are at risk.

  • The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference
    Motley Foollast month

    The 3 Best-Performing Biotech Stocks at the J.P. Morgan Healthcare Conference

    These companies arguably stole the show at J.P. Morgan's high-profile healthcare conference this year.

  • Motley Foollast month

    3 Biggest Stories at the J.P. Morgan Healthcare Conference This Year

    These stocks skyrocketed following exciting announcements.